Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Clinical trial NCT05442216 · RECRUITING

Trial details

NCT number: NCT05442216
Sponsor: Joshua Zeidner
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2024-05-01
Primary completion: 2030-07-21
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.